ClinicalTrials.gg
CompletedNCT03495960FIORELLAUpdated Jan 30, 2025

Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System

A Phase 2 interventional study of Rituximab and Methotrexate in Primary Central Nervous System Lymphoma, sponsored by International Extranodal Lymphoma Study Group (IELSG). Completed at 34 sites in 4 countries. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2025-01-30.

Sponsored by International Extranodal Lymphoma Study Group (IELSG) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 32 studies testing methotrexate in Lymphoma, Non-Hodgkin — 2 open to participants now, 2 under way, none of them phase 3. Methotrexate · Lymphoma, Non-Hodgkin.

Enrollment
4th of 30
72 · median 30
Started
2019
the only one that year
Phase 2
23 of 32
2 open now
Registered
29th of 32
by date

Among the 32 studies testing methotrexate in Lymphoma, Non-Hodgkin, this one is the 4th largest by enrollment of the 30 interventional ones that give a count, is the only one that started in 2019, is one of 23 in phase 2, and was the 29th registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

2 of the 32 studies testing methotrexate in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 242 Lymphoma, Non-Hodgkin studies recruiting now, 142 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing methotrexate in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

Primary central nervous system lymphomas are rare aggressive malignancies, usually treated in two steps: an induction phase (where a combination of chemotherapy is given) followed by a consolidation phase (where patients usually receive one of the following: whole-brain irradiation, chemotherapy supported by autologous stem-cell transplantation, other type of chemotherapy, or are just observed).

The feasibility of this overall strategy, for several reasons, is limited in elderly patients .

This study involves patients aged ≥70 years. The more fit patients will receive the standard chemotherapy combination (high-dose methotrexate, procarbazine and rituximab) as induction. Responding patients will receive either procarbazine or lenalidomide as maintenance therapy; the aim is to evaluate the efficacy of these two drugs.

The more fragile patients will receive a less aggressive therapy consisting of concomitant whole-brain radiotherapy, temozolomide and rituximab as induction therapy, followed by temozolomide as maintenance treatment; the aim is to evaluate the efficacy of this combination of treatment.

Read the detailed description

Primary central nervous system lymphomas (PCNSL) are rare aggressive malignancies, mostly of B-cell origin, representing 4% of intracranial neoplasms and 4-6% of extranodal non-Hodgkin's lymphomas (NHL). Despite improvements in treatment, PCNSL is associated with an aggressive course and unsatisfactory outcome. The median age at diagnosis is 61 years and age over 60 years has been reported to be an independent factor for a poorer outcome.

The modern treatment of PCNSL includes two phases: induction and consolidation. The induction phase usually consists of a polychemotherapy combination, including high-dose methotrexate as a critical drug, while there are at least four different strategies that can be used as consolidation: whole-brain irradiation, myeloblative chemotherapy supported by autologous stem-cell transplantation, non-myeloblative chemotherapy, observation (only in patients who achieve complete remission after induction).

The feasibility of this overall strategy is limited, for several reasons, in elderly patients with newly diagnosed PCNSL. High-doses of antimetabolite-based chemotherapy, the standard induction for patients younger than 70 years, is often not feasible in elderly patients. Among maintenance strategies, simple observation results in unacceptably high relapse rate and associated mortality while whole-brain irradiation and aggressive chemotherapies are associated with unacceptable toxicity and poor outcome. Thus, new strategies aimed at obtaining durable responses with an acceptable tolerability and reduced risk of neurocognitive decline are needed and these strategies should be tailored not only based on the patients' age but also on their specific co-morbidities and general health conditions.

For the present trial, all patients aged ≥70 years taken into care at the participating sites will be invited to participate and after informed consent signature their baseline data will be collected in the trial database, including data of patients resulting in screening failure. This will allow to verify any potential screening bias by comparing the characteristics of included and excluded patients. Patients fulfilling the eligibility criteria are then screened for their suitability to receive a more or less aggressive anticancer treatment and assigned to two different treatment strategies accordingly.

Part A:

The more fit patients are assigned to the trial Part A and will receive the standard combination of high-dose methotrexate, procarbazine and rituximab as induction. Responding patients will subsequently be randomized to receive either procarbazine or lenalidomide as maintenance therapy.

Procarbazine is a lipophilic oral alkylating agent, easily crossing the blood brain barrier (up to 100% of plasma levels). There is no known cumulative toxicity for procarbazine and it is therefore currently in use as a viable maintenance treatment option aimed at eliminating residual lymphoma cells in the CNS and reduce the risk of relapse. Lenalidomide is an oral immunomodulatory agent, active against diffuse large B cell lymphoma, the most common category in PCNSL, which can be taken for years, showing an excellent safety profile. On this background, the Part A of the present trial consists of a randomized phase II trial conducted in elderly patients with newly diagnosed PCNSL responsive to high-dose methotrexate-based chemotherapy, comparing two different maintenance strategies: the oral chemotherapeutic drug procarbazine and the oral immunomodulatory agent lenalidomide.

Part B:

The more fragile patients are assigned to the trial Part B and will receive a less aggressive therapy consisting of concomitant whole-brain radiotherapy, temozolomide and rituximab as induction therapy, followed by temozolomide single-agent as maintenance treatment.

Whole-brain radiotherapy is the main therapeutic choice for patients with contraindications to chemotherapy and in particular for elderly patients. Brain irradiation is usually associated with transient disruption of the blood-tumor barrier, occurring from 1 week after the initiation of radiotherapy to 1 month after its completion, during which pharmaceutical agents have maximum access to tumor tissue. Concomitant delivery of active cytostatics, therefore, could result in increased tumor uptake. Concomitant delivery of radiotherapy and temozolomide is currently used as standard approach for the treatment of high-grade gliomas, with acceptable toxicity despite the use of a larger irradiation dose. Based on the above, in the Part B of the present trial, temozolomide and rituximab, two agents active against PCNSL, are delivered concomitantly to whole-brain radiotherapy to obtain a synergistic effect of radiation damage, antineoplastic effect of rituximab and cytostatic and radiomimetic effects of temozolomide. Finally, temozolomide maintenance has shown to be beneficial regarding sustained remission after initial response to induction therapy and its suitability to improve disease control in responding patients not fit for more aggressive therapies will therefore be tested in the Part B of this trial.

03

Conditions studied

  • Primary Central Nervous System Lymphoma

Keywords

  • non-Hodgkin's lymphoma
  • elderly
  • PCNSL
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologically or cytologically assessed diagnosis of CD20+ diffuse large B-cell lymphoma.
  • Diagnostic sample obtained by stereotactic or surgical , CSF cytology examination or vitrectomy.
  • Lymphoma exclusively localized in the central nervous system (brain parenchyma and/or meningeal/CSF dissemination and/or eyes and/or cranial nerves).
  • Previously untreated patients (previous or ongoing therapy admitted).
  • Age ≥70 years
  • Patients not eligible for high-dose chemotherapy supported by stem cell transplant
  • PS ≤3.
  • Adequate bone marrow, cardiac, renal, and hepatic function
  • No previous or concurrent with the exception of surgically cured carcinoma in-situ of the cervix, carcinoma of the skin or other cancers without evidence of disease at least for 3 years (patients with a previous lymphoma at any time are NOT eligible).
  • Absence of any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
  • No concurrent treatment with other experimental drugs.
  • Patients receiving oral lenalidomide or procarbazine must agree to avoid sharing the study medication with another person and to return all unused study drug to the investigator.
  • Male patients must agree to always use a latex or synthetic condom during any sexual contact with females of while taking lenalidomide, during dose interruptions and for up to 7 days after treatment discontinuation, even if they have undergone a successful vasectomy.
  • from the patient, or legal representative, obtained before registration.

Exclusion criteria

Exclusion Criteria:

  • Lymphoma entity other than diffuse large B-cell lymphoma.
  • Extra-CNS disease.
  • Lymphoma exclusively localized in the eyes
  • Lymphoma infiltration of the cranial nerves as exclusive site of disease
  • Previous antineoplastic treatment for the PCNSL.
  • Patients eligible for .
  • - and -positive patients; HBsAg- and HCV-positive patients. HBcAb+ is not exclusion criteria in the absence of detectable levels HBVDNA.
  • disease or immunodeficiency.
  • Severe concomitant illnesses/medical conditions (e.g. impaired respiratory and/or cardiac function, uncontrolled diabetes mellitus despite optimal medical management).
  • Active infectious disease.
  • to any active principle and/or any according to the reported in the Summary of Product Characteristics (SmPCs) of the anticancer drugs used in the study
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Lenalidomide (experimental arm of part A)

    Patients in part A will receive 2 courses of induction chemo-immunotherapy: Rituximab 375 mg/m2 i.v. on days -6, 1, 15, 29; Methotrexate 3 g/m2 0.5 g/m2 in 15 min. +2.5 g/m2 in 3-hr inf. on days 2,16,30; Procarbazine 60 mg/m2/d oral on days 2 to 11. The duration of each treatment course is 43 days. Patients will then be randomized to receive lenalidomide or procarbazine as maintenance therapy. Lenalidomide is given 25 mg/d per os, days 1 to 21 every 4 weeks for 24 courses

    Drug: Rituximab · Drug: Methotrexate · Drug: Procarbazine · Drug: Lenalidomide

  • Active comparator
    Procarbazine (comparator arm of part A)

    Patients in part A will receive 2 courses of induction chemo-immunotherapy: Rituximab 375 mg/m2 i.v. on days -6, 1, 15, 29; Methotrexate 3 g/m2 0.5 g/m2 in 15 min. +2.5 g/m2 in 3-hr inf. on days 2,16,30; Procarbazine 60 mg/m2/d oral on days 2 to 11. The duration of each treatment course is 43 days. Patients will then be randomized to receive lenalidomide or procarbazine as maintenance therapy. Procarbazine is given 100 mg/d per os, days 1 to 5 every 4 weeks for 6 courses

    Drug: Rituximab · Drug: Methotrexate · Drug: Procarbazine

  • Other
    Radiotherapy, temozolomide and rituximab (single arm part B)

    Patients ineligible for high-dose-methotrexate will be treated in the single-arm phase II part B of the trial and will receive * whole-brain radiotherapy (2340 cGy in 5 weekly fractions) * temozolomide 75 mg/m2/d during radiotherapy * 4 weekly doses of rituximab 375 mg/m2, starting on day 2 of the whole-brain radiotherapy. Patients will then receive maintenance therapy with 12 courses of temozolomide administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses.

    Drug: Rituximab · Radiation: Radiotherapy · Drug: Temozolomide

Interventions

  • PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Rituximab is given 375 mg/m2 as standard infusion at days -6, 1, 15 \& 29. Rituximab on day -6 will be delivered only during the first course; it will be delivered between day -6 and day 0 according to clinical requirements and patient's conditions. Some patients would need for a fast chemotherapy starting. PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Rituximab is given 375 mg/m2 in 4 weekly doses, starting on day 2 of radiotherapy.

  • During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Methotrexate is given 3 g/m2 as infusion (0.5 g/m2 in 15 min. + 2.5 g/m2 in 3-hr infusion) on days 2, 16 \& 30

  • PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Procarbazine is given oral 60 mg/m2/d from days 2 to 11 PART A - MANTEINANCE PHASE (control arm) Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course. Procarbazine represents the control arm and is given oral 100 mg/d from day 1 to 5 for 6 courses, every 4 weeks.

  • Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course. Lenalidomide represents the experimental arm and is given oral 25 mg/d from day 1 to 21 for 24 courses; every 4 weeks.

  • RadiationRadiotherapy

    Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the eyes. Photons of 4 - 10 MeV, 180 - 200 cGy per day, 5 weekly fractions will be employed

  • PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Temoyolomide is given 75 mg/m2/d, every day for the whole duration of radiotherapy. PART B - MAINTENANCE PHASE Temozolomide is also given as maintenance in Part B. The treatment consists of 12 courses where temozolomide is administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses,

06

What researchers measure

Primary outcomes

  1. Two years Progression Free Survival (PFS) - part A

    The primary objective is to evaluate whether lenalidomide administered as maintenance treatment after achievement of disease stabilization or better response by standard induction therapy results in a higher 2-year PFS rate as compared to procarbazine maintenance. The corresponding primary endpoint is the difference in 2-years PFS between the two treatment arms.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.

  2. Two years Progression Free Survival (PFS) - part B

    Time frame: From date of maintenance start until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years

Secondary outcomes

  1. Duration of response (part A)

    Difference between the two arms in time from first assessment of response (PR or CR) to relapse/progression

    Time frame: From date of first assessment of response (PR or CR) until the date of first documented progression, assessed up to 2 years from randomization.

  2. Response Rates (part B)

    Proportion of patients showing CR, PR, SD, PD as best response to treatment

    Time frame: From the start of the treatment until disease progression, assessed up to 2 years from start of maintenance.

  3. Overall survival (OS)

    Time frame: From date of induction treatment start until the date of death from any cause or the date of the last visit in patients still alive at study end, assessed up to 2 years from start of maintenance.

  4. Relapse rates and patterns

    Analysis of the following relapse rates and patterns: primary site vs. secondary CNS sites vs. extra-CNS sites; CNS sites: brain, meninges, cranial nerves, and/or eyes

    Time frame: From the start of the treatment until disease progression, assessed up to 2 years from start of maintenance.

  5. Incidence of Treatment-Emergent Adverse Events

    Analysis of adverse events and adverse reactions incidence and severity

    Time frame: From the 2 weeks preceding treatment start through study completion, an average of 2.5 years

  6. Early and late neurotoxicity

    Analysis of incidence and severity of early and late neurotoxicity assessed by specific neuropsychological and quality of life tests up to 2 years from maintenance treatment start

    Time frame: From maintenance up to 2 years.

07

Study locations

34 sites
  • Aarhus University Hospital
    Aarhus, Denmark
  • Odense University Hospital
    Odense, Denmark
  • Oulu University Hospital
    Oulu, Finland
  • Tampere University Hospital
    Tampere, Finland
  • Centro di Riferimento Oncologico
    Aviano, (pn) 33081, Italy
  • Ospedale C.e G. Mazzoni
    Ascoli Piceno, Italy
  • Bari IRCCS Istituto Tumori
    Bari, Italy
  • ASST Spedali Civili di Brescia
    Brescia, Italy
  • Ospedale Antonio Perrino
    Brindisi, Italy
  • Azienda Ospedaliera Universitaria (AOU) Careggi
    Firenze, Italy
  • Meldola, IRST - ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
    Meldola, Italy
  • Milano, IRCCS Ospedale San Raffaele
    Milan, 20132, Italy
  • Milano - Îstituto Besta
    Milan, Italy
  • Milano Niguarda
    Milan, Italy
  • Modena, Policlinico Universitario
    Modena, Italy
  • ASST Monza - Ospedale S. Gerardo
    Monza, Italy
  • Pescara, Presidio Ospedaliero UOS dipartimentale centro di diagnosi e terapia Linfomi
    Pescara, Italy
  • Piacenza
    Piacenza, Italy
  • Ravenna - Ospedale di Ravenna - IRST
    Ravenna, Italy
  • Reggio Emilia - Arcispedale Santa Maria Nuova - IRCCS
    Reggio Emilia, Italy
  • AUSL della Romagna - Presidio Ospedaliero Rimini - Ospedale "Infermi"
    Rimini, Italy
  • Policlinico Umberto I - Università La Sapienza
    Roma, Italy
  • Roma - Unicampus-Bio
    Roma, Italy
  • S. Giovanni Rotondo - Casa Sollievo della sofferenza
    San Giovanni Rotondo, Italy
  • Siena - Azienda Ospedaliera Universitaria Senese
    Siena, Italy
  • Terni - Ospedale di Terni
    Terni, Italy
  • Torino neurooncologia - AOU CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO
    Torino, Italy
  • Tricase - Ospedale "Card. G. Panico"
    Tricase, Italy
  • Udine, Azienda Ospedaliera Universitaria
    Udine, Italy
  • Basel - Universitätsspital
    Basel, Switzerland
  • IOSI - Oncology Institute of Southern Switzerland
    Bellinzona, 6500, Switzerland
  • Bern - Inselspital
    Bern, Switzerland
  • St. Gallen - Kantonsspital
    Saint Gallen, Switzerland
  • Universitätsspital Zürich
    Zürich, CH-8091, Switzerland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Dec 2024, 65 months.

Of 170 non-industry phase 2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 111. This study's 65 months is close to that.

Counting every sponsor, half of 220 studies reached it within 65 months; a quarter within 41 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2018
First posted
Apr 12, 2018
StartActual
Jun 15, 2019
Primary completionActual
Dec 12, 2024
CompletionActual
Dec 12, 2024
Last update
Jan 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03495960
Lead sponsor
International Extranodal Lymphoma Study Group (IELSG)
Responsible party
Sponsor
First posted
Apr 12, 2018
Start date
Jun 15, 2019
Primary completion
Dec 12, 2024
Completion
Dec 12, 2024
Last update
Jan 30, 2025

Study contacts

Andrès JM Ferreri, MD
study chair · IRCCS San Raffaele Scientific Institute, Milan, Italy

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methotrexate · Procarbazine · Lenalidomide

Start the discussion